Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series [Yahoo! Finance]
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Chardan's 2 nd Annual Virtual Ophthalmology Summit focused on age-related macular degeneration (AMD) and diabetes-related ocular diseases and featured 8 companies pursuing various differentiated approaches in treating serious eye conditions, including Outlook Therapeutics. As part of the virtual event, Russell Trenary, President and Chief Executive Officer and Lawrence Kenyon, Chief Executive Officer of Outlook Therapeutics participated in a fireside chat hosted by Daniil Gataulin, PhD, Senior Research Analyst at Chardan. A video webcast of the fireside chat is now available here About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell SeriesGlobeNewswire
- Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference SeriesGlobeNewswire
- Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical TrialGlobeNewswire
- Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at Ascendiant Capital Markets from $35.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
OTLK
Earnings
- 8/14/24 - Beat
OTLK
Sec Filings
- 8/14/24 - Form S-8
- 8/14/24 - Form 10-Q
- 8/14/24 - Form 8-K
- OTLK's page on the SEC website